Patologia w obszarach zmniejszonego metabolizmu w badaniu PET-FDG u dzieci z epilepsją spowodowaną dysplazją kory mózgowej
Pathology in resected areas of [18F]FDG PET hypometabolism in pediatric epilepsy patients with focal cortical dysplasia
W skrócie
[Preprint - wstępne wyniki] Badacze przeanalizowali tkanki mózgowe usuniętych u 14 dzieci z oporną epilepsją i dysplazją kory mózgowej, porównując strukturę komórkową ze środka zmian (które widać w obrazowaniu) z obszarami wokół nich. Okazało się, że zmienione komórki są przeważnie w środku zmian (75% przypadków), ale anomalie mogą być też na obrzeżach (62% przypadków). Wszystkie dzieci po operacji uległy całkowitemu ustąpieniu napadów padaczkowych, co sugeruje, że włączenie otaczających obszarów do zabiegu chirurgicznego było uzasadnione i bezpieczne.
Oryginalny abstract (angielski)
Introduction: [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) frequently reveals hypometabolism extending beyond the epileptogenic zone in focal cortical dysplasia (FCD). However, it is unclear whether these peripheral hypometabolic areas harbour pathological cells potentially contributing to seizure generation. This study characterized histopathology in the lesion epicentre vs borders of the FDG-PET hypometabolism-informed resections in pediatric patients undergoing epilepsy surgery. Methods: Fourteen children with intractable, extra-temporal focal epilepsy (mean age 9.0±5.0 years; 9 female) were retrospectively reviewed. FDG-PET contributed significantly to surgical planning in all cases, with the resection encompassing the visually-apparent MRI signal abnormalities as well as areas of surrounding hypometabolism when safely feasible. Multiple pathological specimens were obtained from the epicentre and surrounding hypometabolic areas. Overall, 136 specimens were analyzed: 64 epicentre (mean 4.6±3.2/patient) and 72 border (mean 5.1±3.5/patient). Results: Pathology was identified in 75% of epicentre specimens (59% with frank FCD (fFCD) IIa/b, 16% with dysmorphic neurons only (DNO)). Border specimens showed pathology in 62% (31% fFCD IIa/b, 31% DNO). We fitted a Bayesian logistic mixed model with pathology as outcome variable, location as predictor, and subject as a random effect. Compared to negative pathology, the log-odds of fFCD in the epicentre was 1.00 (confidence interval (CI) 0.32, 1.77) and -1.25 in the border (CI -2.17, -0.40). The log-odds of DNO vs negative pathology was non-significant in both locations. All patients achieved Engel Ia status at one-year follow-up with no long-term neurological deficits. Conclusion: These findings suggest a gradient of histopathology, with fFCD concentrated in the epicentre and DNO present in both the epicentre and hypometabolic borders. Thus, FDG-PET may be used to better detect the histopathological borders of FCD type II, and the high seizure-freedom rate presented here supports the inclusion of these surrounding hypometabolic regions in the surgical resection (when safe to do so), potentially improving the likelihood of removing epileptogenic cells.